• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed

    2/10/21 6:06:26 AM ET
    $VIE
    Major Pharmaceuticals
    Health Care
    Get the next $VIE alert in real time by email
    SC 13D/A 1 a21-6078_1sc13da.htm SC 13D/A

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13D

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 2)

     

    Viela Bio, Inc.

    (Name of Issuer)

     

    Common Stock, Par Value $0.001

    (Title of Class of Securities)

     

    926613100

    (CUSIP Number)

     

    Geraine Chan

    Boundless Meadow Limited

    Suite 1518, Two Pacific Place,

    88 Queensway, Hong Kong

    People’s Republic of China

    +852 3987 1788

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

     

    January 31, 2021

    (Date of Event which Requires Filing of this Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 1(f) or 1(g), check the following box. o

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section of the Exchange Act but shall be subject to all other provisions of the Exchange Act (however, see the Notes).

     


     

    SCHEDULE 13D

     

    CUSIP No. 926613100

     

     

     

     

     

     

     

     

     

    1.

     

    Names of Reporting Persons.

    Boundless Meadow Limited

    2.

     

    Check the Appropriate Box if a Member of a Group (See Instructions).

    (a) o (b) o

    3.

     

    SEC Use Only

    4.

     

    Source of Funds (See Instructions)

    WC

    5.

     

    Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

    o

    6.

     

    Citizenship or Place of Organization

    Cayman Islands

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With

     

    7.

     

    Sole Voting Power

    0

     

    8.

     

    Shared Voting Power

    8,322,353 common stock(1)

     

    9.

     

    Sole Dispositive Power

    0

     

    10.

     

    Shared Dispositive Power

    8,322,353 common stock(1)

    11.

     

    Aggregate Amount Beneficially Owned by Each Reporting Person

    8,322,353 common stock(1)

    12.

     

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

    o

    13.

     

    Percent of Class Represented by Amount in Row (11)

    15.18%(2)

    14.

     

    Type of Reporting Person (See Instructions)

    CO

     


    (1)         Representing 8,322,353 shares of common stock directly held by Boundless Meadow Limited.

    (2)         Percentage calculated based on an aggregate of 54,837,541 shares of common stock outstanding as of November 10, 2020, as reported in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission on November 10, 2020.

     

    2


     

    CUSIP No. 926613100

     

     

     

     

     

     

     

     

     

    1.

     

    Names of Reporting Persons.

    Boyu Capital Fund III, L.P.

    2.

     

    Check the Appropriate Box if a Member of a Group (See Instructions).

    (a) o (b) o

    3.

     

    SEC Use Only

    4.

     

    Source of Funds (See Instructions)

    WC

    5.

     

    Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

    o

    6.

     

    Citizenship or Place of Organization

    Cayman Islands

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With

     

    7.

     

    Sole Voting Power

    0

     

    8.

     

    Shared Voting Power

    8,322,353 common stock(1)

     

    9.

     

    Sole Dispositive Power

    0

     

    10.

     

    Shared Dispositive Power

    8,322,353 common stock(1)

    11.

     

    Aggregate Amount Beneficially Owned by Each Reporting Person

    8,322,353 common stock(1)

    12.

     

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

    o

    13.

     

    Percent of Class Represented by Amount in Row (11)

    15.18%(2)

    14.

     

    Type of Reporting Person (See Instructions)

    PN

     


    (1)         Representing 8,322,353 shares of common stock directly held by Boundless Meadow Limited.

    (2)         Percentage calculated based on an aggregate of 54,837,541 shares of common stock outstanding as of November 10, 2020, as reported in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission on November 10, 2020.

     

    3


     

    CUSIP No. 926613100

     

     

     

     

     

     

     

     

     

    1.

     

    Names of Reporting Persons.

    Boyu Capital General Partner III, L.P.

    2.

     

    Check the Appropriate Box if a Member of a Group (See Instructions).

    (a) o (b) o

    3.

     

    SEC Use Only

    4.

     

    Source of Funds (See Instructions)

    N/A

    5.

     

    Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

    o

    6.

     

    Citizenship or Place of Organization

    Cayman Islands

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With

     

    7.

     

    Sole Voting Power

    0

     

    8.

     

    Shared Voting Power

    8,322,353 common stock(1)

     

    9.

     

    Sole Dispositive Power

    0

     

    10.

     

    Shared Dispositive Power

    8,322,353 common stock(1)

    11.

     

    Aggregate Amount Beneficially Owned by Each Reporting Person

    8,322,353 common stock(1)

    12.

     

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

    o

    13.

     

    Percent of Class Represented by Amount in Row (11)

    15.18%(2)

    14.

     

    Type of Reporting Person (See Instructions)

    PN

     


    (1)         Representing 8,322,353 shares of common stock directly held by Boundless Meadow Limited.

    (2)         Percentage calculated based on an aggregate of 54,837,541 shares of common stock outstanding as of November 10, 2020, as reported in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission on November 10, 2020.

     

    4


     

    CUSIP No. 926613100

     

     

     

     

     

     

     

     

     

    1.

     

    Names of Reporting Persons.

    Boyu Capital General Partner III, Ltd.

    2.

     

    Check the Appropriate Box if a Member of a Group (See Instructions).

    (a) o (b) o

    3.

     

    SEC Use Only

    4.

     

    Source of Funds (See Instructions)

    N/A

    5.

     

    Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

    o

    6.

     

    Citizenship or Place of Organization

    Cayman Islands

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With

     

    7.

     

    Sole Voting Power

    0

     

    8.

     

    Shared Voting Power

    8,322,353 common stock(1)

     

    9.

     

    Sole Dispositive Power

    0

     

    10.

     

    Shared Dispositive Power

    8,322,353 common stock(1)

    11.

     

    Aggregate Amount Beneficially Owned by Each Reporting Person

    8,322,353 common stock(1)

    12.

     

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

    o

    13.

     

    Percent of Class Represented by Amount in Row (11)

    15.18%(2)

    14.

     

    Type of Reporting Person (See Instructions)

    CO

     


    (1)         Representing 8,322,353 shares of common stock directly held by Boundless Meadow Limited.

    (2)         Percentage calculated based on an aggregate of 54,837,541 shares of common stock outstanding as of November 10, 2020, as reported in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission on November 10, 2020.

     

    5


     

    CUSIP No. 926613100

     

     

     

     

     

     

     

     

     

    1.

     

    Names of Reporting Persons.

    Boyu Capital Opportunities Master Fund

    2.

     

    Check the Appropriate Box if a Member of a Group (See Instructions).

    (a) o (b) o

    3.

     

    SEC Use Only

    4.

     

    Source of Funds (See Instructions)

    WC

    5.

     

    Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

    o

    6.

     

    Citizenship or Place of Organization

    Cayman Islands

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With

     

    7.

     

    Sole Voting Power

    0

     

    8.

     

    Shared Voting Power

    300,000 common stock(1)

     

    9.

     

    Sole Dispositive Power

    0

     

    10.

     

    Shared Dispositive Power

    300,000 common stock(1)

    11.

     

    Aggregate Amount Beneficially Owned by Each Reporting Person

    300,000 common stock(1)

    12.

     

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

    o

    13.

     

    Percent of Class Represented by Amount in Row (11)

    0.55%(2)

    14.

     

    Type of Reporting Person (See Instructions)

    CO

     


    (1)         Representing 300,000 shares of common stock directly held by Boyu Capital Opportunities Master Fund.

    (2)         Percentage calculated based on an aggregate of 54,837,541 shares of common stock outstanding as of November 10, 2020, as reported in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission on November 10, 2020.

     

    6


     

    CUSIP No. 926613100

     

     

     

     

     

     

     

     

     

    1.

     

    Names of Reporting Persons.

    Boyu Capital Investment Management Ltd.

    2.

     

    Check the Appropriate Box if a Member of a Group (See Instructions).

    (a) o (b) o

    3.

     

    SEC Use Only

    4.

     

    Source of Funds (See Instructions)

    N/A

    5.

     

    Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

    o

    6.

     

    Citizenship or Place of Organization

    Cayman Islands

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With

     

    7.

     

    Sole Voting Power

    0

     

    8.

     

    Shared Voting Power

    300,000 common stock(1)

     

    9.

     

    Sole Dispositive Power

    0

     

    10.

     

    Shared Dispositive Power

    300,000 common stock(1)

    11.

     

    Aggregate Amount Beneficially Owned by Each Reporting Person

    300,000 common stock(1)

    12.

     

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

    o

    13.

     

    Percent of Class Represented by Amount in Row (11)

    0.55%(2)

    14.

     

    Type of Reporting Person (See Instructions)

    CO

     


    (1)         Representing 300,000 shares of common stock directly held by Boyu Capital Opportunities Master Fund.

    (2)         Percentage calculated based on an aggregate of 54,837,541 shares of common stock outstanding as of November 10, 2020, as reported in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission on November 10, 2020.

     

    7


     

    CUSIP No. 926613100

     

     

     

     

     

     

     

     

     

    1.

     

    Names of Reporting Persons.

    Boyu Capital Group Holdings Ltd.

    2.

     

    Check the Appropriate Box if a Member of a Group (See Instructions).

    (a) o (b) o

    3.

     

    SEC Use Only

    4.

     

    Source of Funds (See Instructions)

    N/A

    5.

     

    Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

    o

    6.

     

    Citizenship or Place of Organization

    Cayman Islands

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With

     

    7.

     

    Sole Voting Power

    0

     

    8.

     

    Shared Voting Power

    8,622,353 common stock(1)

     

    9.

     

    Sole Dispositive Power

    0

     

    10.

     

    Shared Dispositive Power

    8,622,353 common stock(1)

    11.

     

    Aggregate Amount Beneficially Owned by Each Reporting Person

    8,622,353 common stock(1)

    12.

     

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

    o

    13.

     

    Percent of Class Represented by Amount in Row (11)

    15.72%(2)

    14.

     

    Type of Reporting Person (See Instructions)

    CO

     


    (1)         Consists of (i) 8,322,353 shares of common stock directly held by Boundless Meadow Limited and (ii) 300,000 common stock directly held by Boyu Capital Opportunities Master Fund.

    (2)         Percentage calculated based on an aggregate of 54,837,541 shares of common stock outstanding as of November 10, 2020, as reported in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission on November 10, 2020.

     

    8


     

    CUSIP No. 926613100

     

     

     

     

     

     

     

     

     

    1.

     

    Names of Reporting Persons.

    XYXY Holdings Ltd.

    2.

     

    Check the Appropriate Box if a Member of a Group (See Instructions).

    (a) o (b) o

    3.

     

    SEC Use Only

    4.

     

    Source of Funds (See Instructions)

    N/A

    5.

     

    Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

    o

    6.

     

    Citizenship or Place of Organization

    British Virgin Islands

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With

     

    7.

     

    Sole Voting Power

    0

     

    8.

     

    Shared Voting Power

    8,622,353 common stock(1)

     

    9.

     

    Sole Dispositive Power

    0

     

    10.

     

    Shared Dispositive Power

    8,622,353 common stock(1)

    11.

     

    Aggregate Amount Beneficially Owned by Each Reporting Person

    8,622,353 common stock(1)

    12.

     

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

    o

    13.

     

    Percent of Class Represented by Amount in Row (11)

    15.72%(2)

    14.

     

    Type of Reporting Person (See Instructions)

    CO

     


    (1)         Consists of (i) 8,322,353 shares of common stock directly held by Boundless Meadow Limited and (ii) 300,000 common stock directly held by Boyu Capital Opportunities Master Fund.

    (2)         Percentage calculated based on an aggregate of 54,837,541 shares of common stock outstanding as of November 10, 2020, as reported in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission on November 10, 2020.

     

    9


     

    CUSIP No. 926613100

     

     

     

     

     

     

     

     

     

    1.

     

    Names of Reporting Persons.

    Xiaomeng Tong

    2.

     

    Check the Appropriate Box if a Member of a Group (See Instructions).

    (a) o (b) o

    3.

     

    SEC Use Only

    4.

     

    Source of Funds (See Instructions)

    N/A

    5.

     

    Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

    o

    6.

     

    Citizenship or Place of Organization

    Hong Kong

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With

     

    7.

     

    Sole Voting Power

    0

     

    8.

     

    Shared Voting Power

    8,622,353 common stock(1)

     

    9.

     

    Sole Dispositive Power

    0

     

    10.

     

    Shared Dispositive Power

    8,622,353 common stock(1)

    11.

     

    Aggregate Amount Beneficially Owned by Each Reporting Person

    8,622,353 common stock(1)

    12.

     

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

    o

    13.

     

    Percent of Class Represented by Amount in Row (11)

    15.72%(2)

    14.

     

    Type of Reporting Person (See Instructions)

    IN

     


    (1)         Consists of (i) 8,322,353 shares of common stock directly held by Boundless Meadow Limited and (ii) 300,000 common stock directly held by Boyu Capital Opportunities Master Fund.

    (2)         Percentage calculated based on an aggregate of 54,837,541 shares of common stock outstanding as of November 10, 2020, as reported in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission on November 10, 2020.

     

    10


     

    Item 1. Security and Issuer

     

    Item 1 of the Schedule 13D is hereby amended and restated in its entirety as follows:

     

    This Amendment No. 2 to Schedule 13D (the “Amendment No.2”) amends and supplements the statement on Schedule 13D that was originally filed on October 17, 2019, as amended and supplemented by the Amendment No. 1 filed jointly on June 8, 2020 (as so amended and supplemented, the “Schedule 13D”) by Boundless Meadow Limited (“Boundless Meadow”), Boyu Capital Fund III, L.P. (“BCF III”), Boyu Capital General Partner III, L.P. (“BCGP III LP”), Boyu Capital General Partner III, Ltd. (“BCGP III Ltd”), Boyu Capital Opportunities Master Fund (“BCOMF”), Boyu Capital Investment Management Ltd. (“BCIM”), Boyu Capital Group Holdings Ltd. (“BCGH”), XYXY Holdings Ltd. (“XYXY Holdings”) and Xiaomeng Tong (“Mr. Tong”, together with Boundless Meadow, BCF III, BCGP III LP, BCGP III Ltd, BCOMF, BCIM, BCGH and XYXY Holdings, the “Reporting Persons”). The class of equity securities to which this statement relates is the common stock, $0.001 par value per share (the “Common Stock”), of Viela Bio, Inc., a Delaware corporation (the “Company”). The principal executive offices of the Company are located at One MedImmune Way, First Floor, Area Two, Gaithersburg, Maryland 20878. The Common Stock are listed on The Nasdaq Global Select Market under the symbol “VIE.”

     

    Capitalized terms used and not defined in this Amendment No.2 shall have the meanings set forth in the Schedule 13D. Except as otherwise provided herein, all Items of the Schedule 13D remain unchanged.

     

    Item 4. Purpose of Transaction.

     

    Item 4 of the Schedule 13D is hereby amended by adding the following text immediately prior to the final paragraph thereof:

     

    On January 31, 2021, the Company, Horizon Therapeutics USA, Inc., a Delaware corporation (“Parent”), Teiripic Merger Sub, Inc., a Delaware corporation and a direct wholly-owned subsidiary of Parent (“Purchaser”), and solely for purposes of Sections 6.7 and 9.12 of the Merger Agreement (as defined below), Horizon Therapeutics plc, a public limited company organized under the laws of Ireland, entered into a definitive Agreement and Plan of Merger (the “Merger Agreement”), pursuant to which Parent, through Purchaser, will commence a tender offer (the “Offer”) to acquire all of the outstanding shares of the Company’s Common Stock, at a price of $53.00 per share in cash, without interest, subject to any applicable withholding taxes. If successful, upon the terms and conditions set forth in the Merger Agreement, the Offer will be followed by a merger of Purchaser with and into the Company, with the Company continuing as the surviving corporation and as a direct wholly-owned subsidiary of Parent.

     

    As a condition to the willingness of Parent and Purchaser to enter into the Merger Agreement and as an inducement in consideration therefor, on January 31, 2021, Boundless Meadow and BCOMF entered into a tender and support agreement (the “Tender and Support Agreement”) with Parent and Purchaser, pursuant to which each of Boundless Meadow and BCOMF has agreed to tender into the Offer all shares of Common Stock beneficially owned by it (and all other shares of Common Stock that it may acquire from time to time, collectively the “Subject Securities”) and to vote or deliver a written consent with respect to all of the Subject Shares in favor of the Merger, the execution and delivery by the Company of the Merger Agreement and any other transactions contemplated thereunder, unless and until the Tender and Support Agreement has been terminated in accordance with its terms.

     

    The foregoing description of the Tender and Support Agreement is not intended to be complete and is qualified in its entirety by reference to the form of the Tender and Support Agreement, which is attached hereto as Exhibit 5.

     

    Except as set forth in this Schedule 13D and the Tender and Support Agreement, the Reporting Persons do not have any present plans which relate to or would result in any of the actions specified in clauses (a) through (j) of Item 4 of Schedule 13D.

     

    Item 5. Interest in Securities of the Issuer.

     

    Item 5 of the Schedule 13D is hereby amended and supplemented as follows:

     

    (a)-(b) The aggregate number and percentage of shares of Common Stock to which this Amendment No.2 relates is 8,622,353 shares of Common Stock, constituting approximately 15.72% of the Company’s outstanding shares of Common Stock as of November 10, 2020. See Items 11 and 13 of the cover pages to this Amendment No.2 for the aggregate number and percentage of Common Stock that are beneficially owned by each Reporting Person as of the date hereof. See Items 7 through 10 of the cover pages to this Amendment No.2 for the number of Common Stock that are beneficially owned by each Reporting Person as of the date hereof as to whether there is sole or shared power to vote or direct the vote, and sole or shared power to dispose or direct the disposition. Neither the filing of this Amendment No.2 nor any of its contents, however, shall be deemed to constitute an admission by the Reporting Persons that (i) any of BCF III, BCGP III LP, BCGP III Ltd, BCGH, XYXY Holdings and Mr. Tong is the beneficial owner of any of the Common Stock beneficially owned by Boundless Meadow, or (ii) any of BCIM, BCGH, XYXY Holdings and Mr. Tong is the beneficial owner of any of the Common Stock beneficially owned by BCOMF, each for purposes of Section 13(d) of the Exchange Act or for any other purpose, and such beneficial ownership is expressly disclaimed. The aggregate number and percentage of shares of Common Stock reported herein are based upon an aggregate of 54,837,541 shares of common stock outstanding as of November 10, 2020, as reported in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission on November 10, 2020.

     

    11


     

    (c) Except as disclosed elsewhere in this Amendment No.2, none of the Reporting Persons, and to the knowledge of the Reporting Persons, none of the general partners, directors or executive officers named on Schedule I hereto, has effected any transactions in the Common Stock in the last 60 days.

     

    (d) To the knowledge of the Reporting Persons, no one other than the Reporting Persons, or the partners, members, affiliates or shareholders of the Reporting Persons has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares of Common Stock covered by this Amendment No.2.

     

    (e) Not applicable.

     

    Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to the Securities of Issuer.

     

    Item 6 of the Schedule 13D is hereby amended by adding the following immediately before the final paragraph thereof:

     

    Information about the Tender and Support Agreement set forth or incorporated by reference in Item 4 of this Amendment No.2 is incorporated by reference into this Item 6.

     

    Item 7. Materials to be Filed as Exhibits.

     

    Item 7 is hereby amended by adding the following exhibits in appropriate numerical order.

     

    Exhibit 5                                              Form of Tender and Support Agreement (incorporated herein by reference to the form of Tender and Support Agreement filed as Exhibit 10.1 to the Form 8-K filed by the Company on February 1, 2021)

     

    12


     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: February 10, 2021

     

     

    Boundless Meadow Limited

     

     

     

    By:

    /s/ Yong Leong Chu

     

     

    Name:

    Yong Leong Chu

     

     

    Title:

    Director

     

     

     

    Boyu Capital Fund III, L.P.

     

     

     

    By: Boyu Capital General Partner III, L.P.

     

    By: Boyu Capital General Partner III, Ltd.

     

     

     

    By

    /s/ Yong Leong Chu

     

     

    Name:

    Yong Leong Chu

     

     

    Title:

    Director

     

     

     

    Boyu Capital General Partner III, L.P.

     

     

     

    By: Boyu Capital General Partner III, Ltd.

     

     

     

    By

    /s/ Yong Leong Chu

     

     

    Name:

    Yong Leong Chu

     

     

    Title:

    Director

     

     

     

    Boyu Capital General Partner III, Ltd.

     

     

     

    By:

    /s/ Yong Leong Chu

     

     

    Name:

    Yong Leong Chu

     

     

    Title:

    Director

     

    13


     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: February 10, 2021

     

     

    Boyu Capital Opportunities Master Fund

     

     

     

    By:

    /s/ Yong Leong Chu

     

     

    Name:

    Yong Leong Chu

     

     

    Title:

    Director

     

    14


     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: February 10, 2021

     

     

    Boyu Capital Investment Management Ltd.

     

     

     

    By:

    /s/ Qi Zhou

     

     

    Name:

    Qi Zhou

     

     

    Title:

    Director

     

     

     

    Boyu Capital Group Holdings Ltd.

     

     

     

    By:

    /s/ Yong Leong Chu

     

     

    Name:

    Yong Leong Chu

     

     

    Title:

    Director

     

     

     

    XYXY Holdings Ltd.

     

     

     

    By:

    /s/ Yong Leong Chu

     

     

    Name:

    Yong Leong Chu

     

     

    Title:

    Director

     

    15


     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: February 10, 2021

     

     

    Xiaomeng Tong

     

     

     

    By:

    /s/ Xiaomeng Tong

     

    16


     

    Get the next $VIE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VIE

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $VIE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Viela Bio Reports Fourth Quarter and Full Year 2020 Operating and Financial Results

      GAITHERSBURG, Md., March 01, 2021 (GLOBE NEWSWIRE) -- Viela Bio (Nasdaq:VIE), a biotechnology company dedicated to the discovery, development and commercialization of novel treatments for patients suffering from autoimmune and severe inflammatory diseases, today reported financial results and provided program and business highlights for the fourth quarter and full year ended December 31, 2020. “2020 was a year of great progress for Viela, despite the many external challenges resulting from the COVID-19 global pandemic,” said Bing Yao, Ph.D., Chief Executive Officer at Viela Bio. “Most significantly, we received FDA approval for UPLIZNA® to treat adult patients with AQP4+ NMOSD and achieve

      3/1/21 4:01:00 PM ET
      $VIE
      Major Pharmaceuticals
      Health Care
    • Viela Bio Announces Additional Positive Results with UPLIZNA® (inebilizumab-cdon) in Patients with Neuromyelitis Optica Spectrum Disorder at the ACTRIMS 2021 Forum

      -No new safety signals were identified with prolonged inebilizumab treatment and inebilizumab-mediated B-cell depletion- -UPLIZNA was shown to be safe and effective in patients with previous exposure to off-label therapy- GAITHERSBURG, Md., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Viela Bio (Nasdaq:VIE), a biotechnology company dedicated to the discovery, development and commercialization of novel treatments for patients suffering from autoimmune and severe inflammatory diseases, today reported updated safety, efficacy and long-term use results of UPLIZNA® (inebilizumab-cdon), including interim data from the open-label extension period (OLP) of the pivotal N-MOmentum trial in patients with neur

      2/25/21 8:30:00 AM ET
      $VIE
      Major Pharmaceuticals
      Health Care
    • Ambrx Appoints Audit Executive Chris Nolet to Board of Directors

      SAN DIEGO--(BUSINESS WIRE)--​Ambrx, a clinical stage biopharmaceutical company using an expanded genetic code to create Engineered Precision Biologics, today announced the appointment of Chris Nolet to the company’s Board of Directors. Mr. Nolet brings extensive experience as a long-time audit partner and business advisor in the life sciences industry, and has assumed the role of Chair of Ambrx’s Audit Committee. “We are delighted that Chris will be joining our Board of Directors given his deep expertise, knowledge base and industry network,” said Feng Tian, Ph.D., President and CEO of Ambrx. “His experience in helping transition clinical stage companies into commercially integra

      2/23/21 4:05:00 PM ET
      $VIE
      $PTE
      $RVNC
      Major Pharmaceuticals
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
      Biotechnology: Pharmaceutical Preparations

    $VIE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Yanling Cao disposed to the issuer $441,084,709 worth of Common Stock (8,322,353 units at $53.00)

      4 - Viela Bio, Inc. (0001734517) (Issuer)

      3/16/21 5:13:43 PM ET
      $VIE
      Major Pharmaceuticals
      Health Care
    • SEC Form 4 filed by Tyrell Rivers

      4 - Viela Bio, Inc. (0001734517) (Issuer)

      3/16/21 8:53:24 AM ET
      $VIE
      Major Pharmaceuticals
      Health Care
    • SEC Form 4 filed by Plc Astrazeneca

      4 - Viela Bio, Inc. (0001734517) (Issuer)

      3/16/21 8:52:55 AM ET
      $VIE
      Major Pharmaceuticals
      Health Care

    $VIE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Viela Bio downgraded by Guggenheim

      Guggenheim downgraded Viela Bio from Buy to Neutral

      2/8/21 11:51:17 AM ET
      $VIE
      Major Pharmaceuticals
      Health Care
    • Viela Bio downgraded by Wedbush

      Wedbush downgraded Viela Bio from Outperform to Neutral

      2/8/21 7:28:49 AM ET
      $VIE
      Major Pharmaceuticals
      Health Care
    • Viela Bio downgraded by Wedbush with a new price target

      Wedbush downgraded Viela Bio from Outperform to Neutral and set a new price target of $43.00

      2/8/21 7:26:43 AM ET
      $VIE
      Major Pharmaceuticals
      Health Care

    $VIE
    Leadership Updates

    Live Leadership Updates

    See more
    • Ambrx Appoints Audit Executive Chris Nolet to Board of Directors

      SAN DIEGO--(BUSINESS WIRE)--​Ambrx, a clinical stage biopharmaceutical company using an expanded genetic code to create Engineered Precision Biologics, today announced the appointment of Chris Nolet to the company’s Board of Directors. Mr. Nolet brings extensive experience as a long-time audit partner and business advisor in the life sciences industry, and has assumed the role of Chair of Ambrx’s Audit Committee. “We are delighted that Chris will be joining our Board of Directors given his deep expertise, knowledge base and industry network,” said Feng Tian, Ph.D., President and CEO of Ambrx. “His experience in helping transition clinical stage companies into commercially integra

      2/23/21 4:05:00 PM ET
      $VIE
      $PTE
      $RVNC
      Major Pharmaceuticals
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
      Biotechnology: Pharmaceutical Preparations

    $VIE
    SEC Filings

    See more

    $VIE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form 15-12B filed by Viela Bio, Inc.

      15-12B - Viela Bio, Inc. (0001734517) (Filer)

      3/25/21 4:01:54 PM ET
      $VIE
      Major Pharmaceuticals
      Health Care
    • SEC Form S-8 POS filed by Viela Bio, Inc.

      S-8 POS - Viela Bio, Inc. (0001734517) (Filer)

      3/15/21 9:15:53 AM ET
      $VIE
      Major Pharmaceuticals
      Health Care
    • SEC Form S-8 POS filed by Viela Bio, Inc.

      S-8 POS - Viela Bio, Inc. (0001734517) (Filer)

      3/15/21 9:12:58 AM ET
      $VIE
      Major Pharmaceuticals
      Health Care
    • SEC Form SC 13D/A filed by Viela Bio, Inc.

      SC 13D/A - Viela Bio, Inc. (0001734517) (Subject)

      3/17/21 7:40:24 AM ET
      $VIE
      Major Pharmaceuticals
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - Viela Bio, Inc. (0001734517) (Subject)

      3/10/21 9:46:40 AM ET
      $VIE
      Major Pharmaceuticals
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - Viela Bio, Inc. (0001734517) (Subject)

      2/16/21 4:22:37 PM ET
      $VIE
      Major Pharmaceuticals
      Health Care